Equity Research Report: Sudarshan Pharma Industries Ltd
Date: January 28, 2026
Current Market Price (CMP): ₹19.30 (Approx)
Market Cap: ~₹464 Cr
1️⃣ Business Model & Work
Sudarshan Pharma Industries Ltd (SPIL) ek diversified Pharma aur Chemical company hai jo manufacturing aur trading dono karti hai.
- Core Business:
- Contract Manufacturing (CDMO): Ye doosri pharma companies ke liye generic formulations (Tablets, Capsules, Creams) manufacture karte hain.
- Specialty Chemicals & Intermediates: Paints, Adhesives aur Pharma APIs banane me use hone wale chemicals supply karte hain. Ye segment inke revenue ka bada hissa hai.
- Generics & Branded Pharma: Inke paas apne brands bhi hain jo domestic market aur exports (Africa, SE Asia) me supply hote hain.
- Key Trigger: Company “Backward Integration” par focus kar rahi hai taaki raw material (Intermediates) khud bana sake aur margins improve kar sake.
2️⃣ Industry & Sector Analysis
- Sector Status: Pharma & Specialty Chemicals.
- Industry Trends: Global generics market me price erosion (daam girna) chal raha hai, jiska asar choti companies ke margins par dikh raha hai.
- Growth Drivers:
- China+1 Strategy: Global companies chemicals ke liye India ko alternate source maan rahi hain.
- CDMO Boom: Badhi pharma companies manufacturing outsource kar rahi hain, jo SPIL jaise players ke liye opportunity hai.
3️⃣ Latest Financial Performance (Consolidated)
⚠️ IMPORTANT: Company ki Board Meeting aaj (28 Jan 2026) schedule thi Q3 results ke liye. Results likhte waqt public domain me confirmed nahi hain, isliye Q2 FY26 (Sep 2025) ko latest reliable data maana gaya hai.
(Figures in ₹ Crores except EPS)
| Particulars | FY 2024 | FY 2025 (Full Year) | Q1 FY26 (Jun ’25) | Q2 FY26 (Sep ’25) |
| Revenue | 468 | 505 | 143.7 | 170.7 |
| Operating Profit | 23 | 40 | 11.0 | 10.9 |
| OPM (%) | 4.9% | 7.9% | 7.6% | 6.4% |
| Net Profit (PAT) | 11.4 | 15.9 | 3.96 | 4.18 |
| EPS (₹) | 0.48 | 0.66 | 0.16 | 0.17 |
Data Source: Screener.in / BSE Filings. (Note: EPS is adjusted for 10:1 Stock Split happened in Nov 2024).
Key Observations:
- Revenue Growth: Q2 me Revenue 32% YoY badhkar ₹170 Cr hua hai, jo strong sales volume dikhata hai.
- Margin Squeeze: Revenue badhne ke bawajood, Net Profit ~28% gira hai (YoY basis par). Iska main karan “Low Margins” hain. Net Profit Margin sirf ~2.45% reh gaya hai, jo business ki pricing power kam hone ka sanket hai.
- Corporate Action: Company ne November 2024 me Stock Split (10:1) kiya tha, jisse share price ₹200+ se adjust hokar ₹20 ki range me aaya hai.
4️⃣ Management & Shareholding (Latest – Dec 2025)
- Promoters: 57.39%. Holding stable hai. Microcap company me >50% promoter holding positive sign hai.
- FIIs: 19.78%. Ye figure surprising hai. Ek microcap (~460 Cr Mcap) me itni badi foreign holding aksar “Structured Funds” ya strategic investors ki hoti hai, na ki standard mutual funds ki. Ise carefully track karna chahiye.
- DIIs / Mutual Funds: 0.00%. Domestic Mutual Funds ka koi bharosa abhi is stock par nahi hai.
- Retail: ~22.8%.
5️⃣ Valuation (Latest Market Data)
- Current PE Ratio: ~25.5x
- Industry Average PE: ~30x – 35x (Chemical/Pharma blended).
- Peer Comparison:
- Sigachi Industries: Trades at ~20x PE.
- Sudarshan Pharma: Valuation “Fair” lag sakti hai, lekin margins (2%) bahut patle hone ke karan ye “Risky Valuation” hai. Zara sa raw material price badha, to profit loss me badal sakta hai.
6️⃣ Future Growth Triggers (3–5 Years)
- New Capacity: Mahad (Maharashtra) me naya plant aur capacity expansion pipeline me hai. Agar ye successfully chalu hota hai, to chemicals segment se margins 8-10% tak ja sakte hain.
- Oncology (Cancer Drugs): Company ne oncology segment me entry lene ke liye subsidiaries (Ratna Lifesciences) acquire ki thi. Ye high-margin segment hai, par scale-up hone me waqt lagega.
- Export Focus: Management ka target Middle East aur Africa me exports badhana hai.
7️⃣ Present Situation (Current Outlook)
- Stock Phase: Correction / Consolidation. Stock split ke baad price ₹19-20 ki range me atka hua hai.
- Immediate Event: Aaj (28 Jan 2026) ke Q3 results decide karenge ki stock ₹20 ka level todega ya ₹15 ki taraf jayega. Agar margins improve nahi huye, to selling pressure aa sakta hai.
- Warning: Stock 52-week high se ~50% correct ho chuka hai. Ye “Value Buy” nahi, balki “Falling Knife” bhi ho sakta hai agar earnings recover nahi hui.
8️⃣ Risk & Red Flags
- Razor Thin Margins: 2-3% Net Profit Margin bahut risky hota hai. Operating leverage bilkul nahi hai.
- Microcap Risk: Market Cap sirf ₹464 Cr hai. Liquidity kam hone ke karan stock me manipulation ya sharp circuits lagne ka dar rehta hai.
- Working Capital: Chemical business me paisa inventory aur debtors me phansa rehta hai. Debtor days check karna zaroori hai (Increasing trend negative hai).
9️⃣ Final Verdict
- Summary: Sudarshan Pharma ek High-Risk Microcap hai. Revenue growth dikh rahi hai (Sales badh rahi hai), lekin Profitability gayab hai. Company “Volume” par khel rahi hai, “Value” par nahi.
- For Conservative Investors: STRICTLY AVOID. Thin margins aur microcap volatility aapke portfolio ke liye suitable nahi hai. Better pharma stocks (like Eris, JB Chemicals) available hain.
- For Aggressive Investors: Sirf tabhi entry lein agar aap High Risk le sakte hain. Current price (₹19.30) par valuation sasta hai, lekin “Trigger” missing hai. Q3 results me agar OPM 8%+ aata hai, to hi Fresh Entry consider karein.
- Target Range: Upside capped lagta hai (~₹24-25). Downside risk ₹15 tak open hai.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.